Top Markets
Coin of the day
Lepu Biopharma Co., Ltd. Lepu Biopharma Co., Ltd.

Lepu Biopharma Co., Ltd.

2157
Classement en actions #9736
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise,... Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
Prix de l'action
$0.53025422
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$956.81M
Changement (1 jour)
0.61%
Changement (1 an)
-52.36%
Pays
CN
Échange Lepu Biopharma Co., Ltd. (2157)

Catégorie

Ratio P/B pour Lepu Biopharma Co., Ltd. (2157)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Lepu Biopharma Co., Ltd., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Lepu Biopharma Co., Ltd. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH